-cell activation and anti--cell therapy for ankylosing spondilitis

This paper discusses the clinical evaluation of b-cell activation and the effectiveness of anti-B-cell therapy (rituximab) for ankylosing spondylitis. In patients with ankylosing spondylitis with a high rate of B-cell activation, the use of anti-B-cell therapy (rituximab) is highly clinically effective.